Flatiron Health has announced the release of six new hematology Panoramic datasets, expanding its real-world evidence platform for blood cancer research. The datasets, which span five B-cell lymphoma subtypes and multiple myeloma, mark a major advance in the company’s efforts to use large-scale, AI-driven data extraction to accelerate hematology research.
For more than a decade, Flatiron has been building and curating the world’s most comprehensive real-world global oncology research database. These hematology datasets showcase what becomes possible when you combine our proven AI capabilities with our commitment to scientific rigor—the potential to deliver more precise, personalized treatments to patients with hematologic malignancies.
Nathan Hubbard, Chief Executive Officer of Flatiron Health
The new datasets are derived from more than 505,000 longitudinal patient records across Flatiron’s national oncology network. Built using the company’s VALID data quality framework, the datasets reflect a sixfold increase in available cohort sizes compared to previous offerings, and deliver enhanced granularity across molecular, treatment, and outcome variables. According to Flatiron, the data enable researchers to interrogate rare hematologic malignancy subgroups and track disease transformations across the full patient journey.
These new hematology datasets represent the culmination of product innovation focused on solving real problems that matter for our partners, like studying novel modalities, niche patient cohorts, and both the predictive and prognostic value of molecular response on patient outcomes. By integrating our AI-powered extraction capabilities with our proven data quality framework, we’re not just delivering more data—we’re delivering the right data at the scale our customers need, all while maintaining the rigorous data standards our partners depend on for regulatory-grade evidence.
Kate Estep, VP, Head of Product at Flatiron Health
Flatiron’s Panoramic platform integrates structured and unstructured data from electronic health records with AI and large language model-driven curation methods. The company says this approach allows extraction and validation of complex clinical variables at a scale not previously possible. Both are critical measures in modern hematology for understanding treatment response, durability, and sequencing in real-world settings.
Flatiron’s hematology research portfolio now encompasses over five million total patient records and more than 1.5 billion curated data points. To date, analyses derived from these datasets have contributed to over 250 peer-reviewed publications examining real-world treatment outcomes, therapy effectiveness, and patient heterogeneity across hematologic malignancies.
Over the past five years we’ve witnessed remarkable breakthroughs in hematologic diseases—including next-generation immunotherapies like CAR T and bispecifics, precision-targeted therapies like menin inhibitors, and ultra-sensitive approaches to monitoring disease like MRD. The pace of these advances means we must also evolve how we generate real-world evidence by comprehensively capturing the clinical nuances and biologic complexity that define modern care. From a clinical perspective, these datasets will transform research in this field because they reflect the true complexity of hematologic cancer care at a scale that simply wasn’t possible before. This evidence foundation will guide better treatment decisions, accelerate new development, and ultimately improve outcomes for patients with blood cancers.
Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health
The new Panoramic datasets are expected to support investigations into rare patient populations, such as those with high-grade B-cell lymphomas harboring MYC, BCL2, or BCL6 rearrangements, as well as multiple myeloma cases characterized by high-risk cytogenetics or extramedullary disease. The expanded data structure enables assessment of real-world progression, molecular response, and adverse events, alongside treatment utilization patterns across inpatient and outpatient settings.
Flatiron plans to present new findings from these datasets at major conferences throughout 2025, including ISPOR Europe and the American Society of Hematology (ASH) Annual Meeting. The company says these presentations will highlight advances in real-world evidence methodologies and applications of AI in hematology.